Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/57/5/458 |
id |
doaj-a0290fd30ed746c1801dd3fe8208c699 |
---|---|
record_format |
Article |
spelling |
doaj-a0290fd30ed746c1801dd3fe8208c6992021-05-31T23:26:55ZengMDPI AGMedicina1010-660X1648-91442021-05-015745845810.3390/medicina57050458Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR InhibitorsAlessandro Rizzo0Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, 40138 Bologna, ItalyDespite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in approximately 50% of cases, and thus, molecularly targeted therapies have been actively explored in this setting. Among these, fibroblast growth factor receptor (FGFR) inhibitors have reported important results, as witnessed by the FDA approval of pemigatinib in previously treated metastatic CCA patients harboring FGFR2 fusion or other rearrangements. Herein, we provide an overview of available evidence on FGFR inhibitors in CCA, especially focusing on the development, pitfalls and challenges of emerging treatments in this setting.https://www.mdpi.com/1648-9144/57/5/458FGFRcholangiocarcinomatargeted therapiesintrahepatic cholangiocarcinomapemigatinib |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alessandro Rizzo |
spellingShingle |
Alessandro Rizzo Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors Medicina FGFR cholangiocarcinoma targeted therapies intrahepatic cholangiocarcinoma pemigatinib |
author_facet |
Alessandro Rizzo |
author_sort |
Alessandro Rizzo |
title |
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors |
title_short |
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors |
title_full |
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors |
title_fullStr |
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors |
title_full_unstemmed |
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors |
title_sort |
targeted therapies in advanced cholangiocarcinoma: a focus on fgfr inhibitors |
publisher |
MDPI AG |
series |
Medicina |
issn |
1010-660X 1648-9144 |
publishDate |
2021-05-01 |
description |
Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in approximately 50% of cases, and thus, molecularly targeted therapies have been actively explored in this setting. Among these, fibroblast growth factor receptor (FGFR) inhibitors have reported important results, as witnessed by the FDA approval of pemigatinib in previously treated metastatic CCA patients harboring FGFR2 fusion or other rearrangements. Herein, we provide an overview of available evidence on FGFR inhibitors in CCA, especially focusing on the development, pitfalls and challenges of emerging treatments in this setting. |
topic |
FGFR cholangiocarcinoma targeted therapies intrahepatic cholangiocarcinoma pemigatinib |
url |
https://www.mdpi.com/1648-9144/57/5/458 |
work_keys_str_mv |
AT alessandrorizzo targetedtherapiesinadvancedcholangiocarcinomaafocusonfgfrinhibitors |
_version_ |
1721417527727226880 |